Goldman Sachs Group Inc Sorrento Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.74 - $1.83 $174,883 - $432,482	-236,329 Reduced 7.85%	2,773,811 $2.47 Million
Q4 2022 Feb 13, 2023	SELL	$0.74 - $1.83 $174,883 - $432,482	-236,329 Reduced 7.85%	2,773,811 $2.47 Million
Q3 2022 May 14, 2024	BUY	$1.51 - $2.88 $1.62 Million - $3.08 Million	1,070,161 Added 55.16%	3,010,140 $4.73 Million
Q3 2022 Nov 10, 2022	BUY	$1.51 - $2.88 $1.62 Million - $3.08 Million	1,070,161 Added 55.16%	3,010,140 $4.73 Million
Q2 2022 May 14, 2024	BUY	$1.24 - $2.33 $2.41 Million - $4.52 Million	1,939,979 New	1,939,979 $3.9 Million
Q2 2022 Aug 15, 2022	BUY	$1.24 - $2.33 $450,012 - $845,587	362,913 Added 23.01%	1,939,979 $3.9 Million
Q1 2022 May 16, 2022	BUY	$2.0 - $4.9 $1.89 Million - $4.63 Million	944,285 Added 149.23%	1,577,066 $3.68 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $162,819 - $253,158	35,015 Added 5.86%	632,781 $2.94 Million
Q3 2021 Nov 10, 2021	BUY	$7.41 - $10.99 $4.43 Million - $6.57 Million	597,766 New	597,766 $4.56 Million

5.48M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.